Loading...
DR Reddys Laboratories Limited — Ondansetron Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #13 for Ondansetron · $1.9M export value · DGFT Verified
DR Reddys Laboratories Limited is the #13 Indian exporter of Ondansetron with $1.9M in export value and 58 verified shipments. DR Reddys Laboratories Limited holds a 1.6% market share in Ondansetron exports across 3 countries. The company exports 37 pharmaceutical products worth $62.4M across 17 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $815.7K | 27 | 50.0% |
| AUSTRALIA | $799.7K | 30 | 49.0% |
| ROMANIA | $17.1K | 1 | 1.1% |
DR Reddys Laboratories Limited exports Ondansetron to 3 countries. The largest destination is UNITED STATES accounting for 50.0% of DR Reddys Laboratories Limited's Ondansetron shipments, followed by AUSTRALIA (49.0%) and ROMANIA (1.1%). These destinations reflect DR Reddys Laboratories Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DR REDDY S LABORATORIES AUSTRALIA PTY LTD | AUSTRALIA | $432.6K | 11 |
| DR REDDYS LABORATORIES INC | UNITED STATES | $420.0K | 13 |
| DR REDDY SLABORATORIES INC | UNITED STATES | $395.6K | 14 |
| DR REDDY S LABORATORIES AUSTRALIA PTY LIMITED | AUSTRALIA | $233.1K | 12 |
| DR REDDY S LABORATORIES AUSTRALIA NA | AUSTRALIA | $59.4K | 2 |
| DR REDDYS LABORATORIES AUSTRALIA PTY LIMITED | AUSTRALIA |
India exported $100.2M worth of Ondansetron through 8,469 shipments from 537 suppliers to 157 countries, serving 1,636 buyers globally. DR Reddys Laboratories Limited contributes $1.9M to this total, accounting for 1.6% of India's Ondansetron exports. DR Reddys Laboratories Limited ships Ondansetron to 3 countries through 8 buyers.
DR Reddys Laboratories Limited's average Ondansetron shipment value is $33.4K per consignment, based on 58 shipments totaling $1.9M. The largest destination is UNITED STATES (50.0% of DR Reddys Laboratories Limited's Ondansetron exports).
DR Reddys Laboratories Limited ranks #13 among 537 Indian Ondansetron exporters with a 1.6% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($31.2M), GLENMARK PHARMACEUTICALS LIMITED ($15.9M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($10.8M). DR Reddys Laboratories Limited processed 58 shipments to 3 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ONDANSETRON SZ ODT 8MG 10'S/PAC 51328PACKSX10'S/PAC=513280.NOS | $50.0K | 1 |
| ONDANSETRON ODT-DRLA 4 MG ORALLY DISINTE | $50.0K | 1 |
| Ondansetron SZ ODT 4 MG [10's pack] Ondansetron tablet 83280 packs x10's = 832800 Nos | $50.0K | 1 |
| Ondansetron SZ ODT 4 MG [10's pack] Ondansetron tablet 83160 packs x10's = 831600 Nos | $50.0K | 1 |
| ONDANSETRON SZ ODT 8 MG 10'S/PAC 43456 PACKS | $50.0K | 1 |
| ONDANSETRON SZ ODT 8 MG 10'S/PAC 43904 PACKS | $50.0K | 1 |
| ONDANSETRON SZ ODT 4 MG ORALLY DISINTEGRATING TABLETS ONDANSETRON 10S TOTAL QTY PACKS 78600X10S=786000 NOS | $50.0K | 1 |
| ONDANSETRON SZ ODT 8 MG ORALLY DISINTEGRATING TABLETS ONDANSETRON 10STOTAL QTYPACKS 42688X10S=426880 NOS | $50.0K |
What DR Reddys Laboratories Limited must comply with to export Ondansetron to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 11 | IPCA LABORATORIES LIMITED | $2.8M | 80 | 3 | $35.4K |
| 12 | INTAS PHARMACEUTICALS LIMITED | $2.5M | 511 | 15 | $4.9K |
| 13 | DR REDDYS LABORATORIES LIMITED ★ | $1.9M | 58 | 3 | $33.4K |
| 14 | NATCO PHARMA LIMITED | $1.6M | 90 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,058 | 12.5% |
| NHAVA SHEVA SEA (INNSA1) | 1,026 | 12.1% |
| SAHAR AIR | 993 | 11.7% |
| HYDERABAD ICD (INSNF6) | 509 | 6.0% |
| HYDERABAD ICD | 448 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 343 | 4.1% |
| DELHI AIR CARGO ACC (INDEL4) | 265 | 3.1% |
| AHEMDABAD AIR ACC (INAMD4) | 224 | 2.6% |
DR Reddys Laboratories Limited also exports these gastrointestinal products. Each links to the detailed product page.
The global pharmaceutical export landscape has been significantly influenced by recent geopolitical events. The 2026 Strait of Hormuz crisis, initiated by military conflicts involving the United States, Israel, and Iran, led to the effective halt of shipping traffic through this critical maritime route, disrupting approximately 20% of the world's daily oil supply and causing a surge in global energy prices. (en.wikipedia.org) This disruption has had a cascading effect on shipping costs and insurance premiums, directly impacting Indian pharmaceutical exporters like Dr. Reddy's, which rely on these routes for timely delivery of products to key markets.
Simultaneously, the 2025–26 United States–India diplomatic and trade crisis, marked by the imposition of a 50% tariff on Indian exports by the U.S., has posed additional challenges. These tariffs have increased the cost of Indian pharmaceutical products in the U.S. market, potentially affecting the competitiveness of companies like Dr. Reddy's. (en.wikipedia.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. Dr. Reddy's has been proactive in adhering to these regulations, ensuring that its products meet the stringent safety and traceability standards mandated by the EU, thereby maintaining its market access and reputation.
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Dr. Reddy's has demonstrated a commitment to quality by securing approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). The company's recent Biologics License Application (BLA) submission for a proposed interchangeable biosimilar to Orencia® (abatacept) underscores its adherence to rigorous regulatory processes. (stockwatch.com)
However, the company has faced regulatory challenges, such as the tax audit decision from the Russian Federal Tax Service in January 2026, which reclassified certain marketing services as taxable, resulting in a penalty. (stocktitan.net) Such incidents highlight the complexities of operating in diverse regulatory environments and the importance of robust compliance frameworks.
DR Reddys Laboratories Limited exports 37 products worth $62.4M. Beyond Ondansetron, top products include Omeprazole, Metoprolol, Diclofenac, Clopidogrel, Fexofenadine. View the complete DR Reddys Laboratories Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Ondansetron — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddys Laboratories Limited's Ondansetron exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddys Laboratories Limited
Full Company Profile →
37 products · $62.4M total trade · 17 categories
| $52.7K |
| 3 |
| DR REDDY S LABORATORIES AUSTRALIA | AUSTRALIA | $21.9K | 2 |
| DR REDDYS LABORATORIES ROMANIA SRL | ROMANIA | $17.1K | 1 |
DR Reddys Laboratories Limited supplies Ondansetron to 8 buyers globally. The largest buyer is DR REDDY S LABORATORIES AUSTRALIA PTY LTD (AUSTRALIA), followed by DR REDDYS LABORATORIES INC (UNITED STATES) and DR REDDY SLABORATORIES INC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| 1 |
| ONDANSETRON TABLETS USP 4MG 30 S 152568X 30 S PACKS= 4577040 NOS | $50.0K | 1 |
| 300001733 ONDANSETRON TABLETS USP 4MG 30S 204432 SU X 30=6132960 NOS | $50.0K | 1 |
DR Reddys Laboratories Limited exports 55 distinct Ondansetron formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ONDANSETRON SZ ODT 8MG 10'S/PAC 51328PACKSX10'S/PAC=513280.N with 1 shipments worth $50.0K.
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 3 |
| $18.0K |
| 15 | MEDCELL PHARMA | $1.3M | 32 | 3 | $40.6K |
DR Reddys Laboratories Limited ranks #13 among 537 Indian Ondansetron exporters. Average shipment value of $33.4K compared to the market average of $186.5K. The closest competitors by value are IPCA LABORATORIES LIMITED and INTAS PHARMACEUTICALS LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 157+ countries, 1,636+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for DR Reddys Laboratories Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ondansetron. For current shipment-level data, contact TransData Nexus.